Tumor antigen–specific T cell therapy
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Tumor antigen–specific T cell therapy, covering 2016-01-01 to 2016-01-01. Get the full timeline:
Most recent: Clinical Trial Update: Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen Combined With Transcatheter Arterial Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma [Phase 1, Phase 2]